On November 6, 2019 Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, reported that two abstracts have been accepted for presentation at the 61st American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in Orlando, FL, taking place from December 7-10, 2019 (Press release, Ryvu Therapeutics, NOV 6, 2019, View Source [SID1234550690]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster presentations are as follows:
Poster Presentation: SEL120 – a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial
Abstract Number: 2651
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Date: Sunday, December 8, 2019
Time: 6:00 p.m. – 8:00 p.m. PST
Location: Orange County Convention Center, Hall B
Poster Presentation: CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation
Abstract Number: 3774
Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III
Date: Monday, December 9, 2019
Time: 6:00 p.m. – 8:00 p.m. PST
Location: Orange County Convention Center, Hall B
To view these abstracts, please visit the American Society of Hematology (ASH) (Free ASH Whitepaper) website located at View Source